menu
    • menu

    Find Ranitidine manufacturers, exporters & distributors on PharmaCompass

    NEW Prospects: 3
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    8

    API Suppliers

    3

    USDMF

    0

    CEP/COS

    0

    JDMF

    1

    EU WC

    0

    KDMF

    0

    NDC API

    0

    VMF

    5

    Listed Suppliers

    0INTERMEDIATES

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    11

    Others

    FINISHED DOSAGE FORMULATIONS

    202

    FDF Dossiers

    1

    FDA Orange Book

    124

    Europe

    0

    Canada

    4

    Australia

    43

    South Africa

    30

    Listed Dossiers

    3PROSPECTS

    3DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    158RELATED EXCIPIENT COMPANIES

    242EXCIPIENTS BY APPLICATIONS

    PATENTS & EXCLUSIVITIES

    0

    US Patents

    0

    US Exclusivities

    0

    Health Canada Patents

    GLOBAL SALES INFORMATION

    US Medicaid

    NA

    Annual Reports

    NA

    Regulatory FDF Prices

    MARKET PLACE

    10

    API

    14

    FDF

    DIGITAL CONTENT

    0

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    124

    News #PharmaBuzz

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 66357-35-5, Ranitidine base, Raticina, Ratic, Ranitidina, Ranitidinum
    Molecular Formula
    C13H22N4O3S
    Molecular Weight
    314.41  g/mol
    InChI Key
    VMXUWOKSQNHOCA-UKTHLTGXSA-N
    Ranitidine
    A non-imidazole blocker of those histamine receptors that mediate gastric secretion (H2 receptors). It is used to treat gastrointestinal ulcers.
    1 2D Structure

    Ranitidine

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    (E)-1-N'-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine
    2.1.2 InChI
    InChI=1S/C13H22N4O3S/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3/h4-5,9,14-15H,6-8,10H2,1-3H3/b13-9+
    2.1.3 InChI Key
    VMXUWOKSQNHOCA-UKTHLTGXSA-N
    2.1.4 Canonical SMILES
    CNC(=C[N+](=O)[O-])NCCSCC1=CC=C(O1)CN(C)C
    2.1.5 Isomeric SMILES
    CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C
    2.2 Synonyms
    2.2.1 MeSH Synonyms

    1. Ah 19065

    2. Ah-19065

    3. Ah19065

    4. Biotidin

    5. Hydrochloride, Ranitidine

    6. N (2-(((5-((dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-n'-methyl-2-nitro-1,1-ethenediamine

    7. Ranisen

    8. Ranitidin

    9. Ranitidine Hydrochloride

    10. Sostril

    11. Zantac

    12. Zantic

    2.2.2 Depositor-Supplied Synonyms

    1. 66357-35-5

    2. Ranitidine Base

    3. Raticina

    4. Ratic

    5. Ranitidina

    6. Ranitidinum

    7. Coralen

    8. Gastrial

    9. Quantor

    10. Rantidine

    11. Zantac

    12. Gastrosedol

    13. Microtid

    14. Ptinolin

    15. Ranidine

    16. Raniogas

    17. Ranisen

    18. Ranitiget

    19. Rantacid

    20. Taural

    21. Duractin

    22. Ulceranin

    23. Weichilin

    24. Xanidine

    25. Zantadin

    26. Achedos

    27. Acidex

    28. Atural

    29. Axoban

    30. Ezopta

    31. Istomar

    32. Logast

    33. Mauran

    34. Quicran

    35. Radinat

    36. Randin

    37. Raniter

    38. Sampep

    39. Urantac

    40. Verlost

    41. Vesyca

    42. Vizerul

    43. Weidos

    44. Zantab

    45. Ranin

    46. Ul-pep

    47. Ranitidine Free Base

    48. Chebi:8776

    49. Ranitidine Impurity J

    50. 1,1-ethenediamine, N-(2-(((5-((dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-n'-methyl-2-nitro-

    51. Ranitidinum [inn-latin]

    52. Ranitidina [inn-spanish]

    53. Zantac (tn)

    54. Chembl512

    55. 1,1-ethenediamine, N-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-n'-methyl-2-nitro-

    56. 66357-35-5 (free Base)

    57. Ncgc00015876-07

    58. Dsstox_cid_25191

    59. Dsstox_rid_80738

    60. Dsstox_gsid_45191

    61. Ranitidine [usan:ban:inn]

    62. Rnd

    63. Ranitidine (tn)

    64. {2-[({5-[(dimethylamino)methyl]furan-2-yl}methyl)sulfanyl]ethyl}[(e)-1-(methylamino)-2-nitroethenyl]amine

    65. Dimethyl[(5-{[(2-{[(e)-1-(methylamino)-2-nitroethenyl]amino}ethyl)sulfanyl]methyl}furan-2-yl)methyl]amine

    66. Cas-66357-35-5

    67. (e)-n-(2-(((5-((dimethylamino)methyl)furan-2-yl)methyl)thio)ethyl)-n-methyl-2-nitroethene-1,1-diamine

    68. 71130-06-8

    69. Ranitidine (usan/inn)

    70. Gavilast

    71. Sr-01000075288

    72. (e)-ranitidine

    73. Tocris-1967

    74. Lopac-r-101

    75. Prestwick2_000201

    76. Spectrum5_001189

    77. Epitope Id:127515

    78. Ranitidine Hcl 1/2 Type

    79. Lopac0_001073

    80. N'-[2-[[5-(dimethylaminomethyl)-2-furyl]methylsulfanyl]ethyl]-n-methyl-2-nitro-ethene-1,1-diamine Hydrochloride

    81. Bidd:gt0179

    82. Spectrum1501151

    83. Gtpl1234

    84. Bdbm22893

    85. Chebi:92246

    86. Hms501f22

    87. N-[2-[[5-[(dimethylamino)methyl]furfuryl]thio]ethyl]-n'-methyl-2-nitro-1,1-ethenediamine

    88. Bdbm237183

    89. Dtxsid101112063

    90. Hms1921l07

    91. Hms2092h15

    92. Hms3886a16

    93. Pharmakon1600-01501151

    94. Ranitidine (form I And Form Ii)

    95. Bcp21325

    96. Hy-b0693

    97. Zinc1530728

    98. Tox21_110250

    99. Tox21_302372

    100. Ccg-39025

    101. Mfcd00081180

    102. Nsc757851

    103. S5662

    104. Stk619092

    105. Akos005552967

    106. Tox21_110250_1

    107. Ks-5230

    108. Sdccgsbi-0051043.p004

    109. Idi1_000440

    110. Ncgc00015876-01

    111. Ncgc00015876-02

    112. Ncgc00015876-03

    113. Ncgc00015876-04

    114. Ncgc00015876-05

    115. Ncgc00015876-06

    116. Ncgc00015876-08

    117. Ncgc00015876-09

    118. Ncgc00015876-11

    119. Ncgc00015876-16

    120. Ncgc00018108-01

    121. Ncgc00018108-02

    122. Ncgc00018108-03

    123. Ncgc00024387-02

    124. Ncgc00094913-01

    125. Ncgc00094913-02

    126. Ncgc00094913-03

    127. Ncgc00094913-04

    128. Ncgc00094913-05

    129. Ncgc00256269-01

    130. ({5-[(2-{[(1e)-1-(methylamino)-2-nitrovinyl]amino}ethylthio)methyl](2-furyl)}m Ethyl)dimethylamine

    131. (e)-n-{2-[({5-[(dimethylamino)methyl]-2-furyl}methyl)sulfanyl]ethyl}-n'-methyl-2-nitroethene-1,1-diamine

    132. (e)-n-{2-[({5-[(dimethylamino)methyl]furan-2-yl}methyl)sulfanyl]ethyl}-n'-methyl-2-nitroethene-1,1-diamine

    133. 82530-72-1

    134. Ac-12712

    135. Br166204

    136. Sbi-0051043.p003

    137. Cas-66357-59-3

    138. Cs-0009591

    139. D00422

    140. D97790

    141. Ab00052223-10

    142. Ab00052223_11

    143. Ab00052223_12

    144. 357r355

    145. A835434

    146. A899862

    147. L000504

    148. Sr-01000075288-3

    149. Brd-k70505054-001-02-9

    150. Q21971328

    151. N-[2-[[5-[(dimethylamino)methyl]furfuryl]thio]ethyl]-n'-methyl-2-nitro-1,1-ethylenediamine

    152. (1e)-n-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-n'-methyl-2-nitro-1,1-ethenediamine

    153. (e)-1-n'-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-1-n-methyl-2-nitroethene-1,1-diamine

    154. (e)-n-(2-((5-((dimethylamino)methyl)furan-2-yl)methylthio)ethyl)-n-methyl-2-nitroethene-1,1-diamine

    155. (e)-n1'-[2-[[5-(dimethylaminomethyl)-2-furyl]methylsulfanyl]ethyl]-n1-methyl-2-nitro-ethene-1,1-diamine

    156. (e)-n1'-[2-[[5-[(dimethylamino)methyl]-2-furyl]methylsulfanyl]ethyl]-n1-methyl-2-nitro-ethene-1,1-diamine;ranitidine Base

    157. 1,1-ethenediamine, N-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-n'-methyl-2-nitro-, (e)-

    158. N-[(e)-1-(methylamino)-2-nitroethenyl]-2-[[[2-[(dimethylamino)methyl]-5-furanyl]methyl]thio]ethanamine

    159. N-[2-[[[5-[(dimethylamino)methyl]-2 -furanyl]methyl]thio]ethyl]-n'-methyl-2-nitro-1,1-ethanediamine

    160. N-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-n'-methyl-2-nitro-1,1-ethenediamine

    161. N-[2-[[5-(dimethylaminomethyl)furan-2-yl]methylsulfanyl]ethyl]-n'-methyl-2-nitroethene-1,1-diamine

    162. N-[2-[[5-[(dimethylamino)methyl]furfuryl]thio]ethyl]-n'-methyl-2-nitrovinylidenediamine Monohydrochloride;ranitidine Hcl

    163. N1'-[2-[[5-[(dimethylamino)methyl]-2-furanyl]methylthio]ethyl]-n1-methyl-2-nitroethene-1,1-diamine

    2.3 Create Date
    2005-03-27
    3 Chemical and Physical Properties
    Molecular Weight 314.41 g/mol
    Molecular Formula C13H22N4O3S
    XLogP30.3
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count7
    Rotatable Bond Count9
    Exact Mass314.14126175 g/mol
    Monoisotopic Mass314.14126175 g/mol
    Topological Polar Surface Area112 Ų
    Heavy Atom Count21
    Formal Charge0
    Complexity347
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count1
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 4  
    Drug NameRanitidine
    PubMed HealthRanitidine
    Drug ClassesAntiulcer, Gastric Acid Secretion Inhibitor
    Drug LabelThe active ingredient in ZANTAC 150 Tablets, ZANTAC 300 Tablets, and ZANTAC Syrup is ranitidine hydrochloride (HCl), USP, a histamine H2-receptor antagonist. Chemically it is N[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N-methyl-2...
    Active IngredientRanitidine
    Dosage FormSolution
    Routeoral
    Strength15mg/ml
    Market StatusTentative Approval
    CompanyActavis Elizabeth

    2 of 4  
    Drug NameZantac
    PubMed HealthRanitidine (Injection)
    Drug ClassesAntiulcer, Gastric Acid Secretion Inhibitor
    Drug LabelThe active ingredient in ZANTAC 150 Tablets, ZANTAC 300 Tablets, and ZANTAC Syrup is ranitidine hydrochloride (HCl), USP, a histamine H2-receptor antagonist. Chemically it is N[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N-methyl-2...
    Active IngredientRanitidine hydrochloride
    Dosage FormSyrup; Injectable
    RouteInjection; Oral
    Strengtheq 15mg base/ml; eq 25mg base/ml
    Market StatusPrescription
    CompanyCovis Injectables; Glaxo Grp

    3 of 4  
    Drug NameRanitidine
    PubMed HealthRanitidine
    Drug ClassesAntiulcer, Gastric Acid Secretion Inhibitor
    Drug LabelThe active ingredient in ZANTAC 150 Tablets, ZANTAC 300 Tablets, and ZANTAC Syrup is ranitidine hydrochloride (HCl), USP, a histamine H2-receptor antagonist. Chemically it is N[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N-methyl-2...
    Active IngredientRanitidine
    Dosage FormSolution
    Routeoral
    Strength15mg/ml
    Market StatusTentative Approval
    CompanyActavis Elizabeth

    4 of 4  
    Drug NameZantac
    PubMed HealthRanitidine (Injection)
    Drug ClassesAntiulcer, Gastric Acid Secretion Inhibitor
    Drug LabelThe active ingredient in ZANTAC 150 Tablets, ZANTAC 300 Tablets, and ZANTAC Syrup is ranitidine hydrochloride (HCl), USP, a histamine H2-receptor antagonist. Chemically it is N[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N-methyl-2...
    Active IngredientRanitidine hydrochloride
    Dosage FormSyrup; Injectable
    RouteInjection; Oral
    Strengtheq 15mg base/ml; eq 25mg base/ml
    Market StatusPrescription
    CompanyCovis Injectables; Glaxo Grp

    4.2 Therapeutic Uses

    Anti-Ulcer Agents; Histamine H2 Antagonists

    National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)

    Ranitidine is effective for the treatment of duodenal or gastric ulcer and relieves symptoms of reflux esophagitis. It heals some NSAID-induced ulcers but does not appear to prevent their initial occurrence. ... Investigationally, this drug prevented aspiration pneumonitis during surgery, and it appears to be useful for the prophylaxis of bleeding due to stress ulcers.

    American Medical Association, Council on Drugs. AMA Drug Evaluations Annual 1994. Chicago, IL: American Medical Association, 1994., p. 901

    Studies show that ranitidine can adequately inhibit acid secretion in patients with gastric hypersecretory disorders, is safe at high doses, does not cause the antiandrogen side effects frequently seen with high doses of cimetidine, & is threefold more potent than cimetidine. Patients relatively resistant to cimetidine will have proportional resistance to ranitidine.

    PMID:6318628 Collen MJ et al; Ann Intern Med 100 (1): 52-8 (1984)

    Ranitidine and a placebo were evaluated in the 28 day treatment of duodenal ulcer through an open randomized study performed in 120 patients. At the end of the treatment, ranitidine demonstrated a significantly higher efficacy on ulcer healing as well as on symptom relief in comparison with placebo (P less than 0.05).

    Giacosa A et al; Scand J Gastroenterol (Suppl) 17 (72): 215-9 (1982)

    For more Therapeutic Uses (Complete) data for RANITIDINE (30 total), please visit the HSDB record page.

    4.3 Drug Warning

    Minor adverse effects occur infrequently (incidence less than 3%) and include headache and rashes that usually subside with continued therapy, malaise, nausea, constipation, dizziness, and abdominal pain. ... Usual doses of ranitidine only rarely produce confusion, gynecomastia, hyperprolactinemia, sexual dysfunction, bradycardia, blood dyscrasias, or hepatitis.

    American Medical Association, Council on Drugs. AMA Drug Evaluations Annual 1994. Chicago, IL: American Medical Association, 1994., p. 901

    Reversible blurred vision suggestive of a change in accommodation has occurred rarely. Exacerbation of ocular pain and blurred vision assoc with increased intraocular pressure and chronic glaucoma have been reported in at least one patient during ranitidine therapy. Loss of color vision, which recurred following rechallenge, has also occurred in at least one patient.

    McEvoy G.K. (ed.). American Hospital Formulary Service-Drug Information 96. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 1996 (Plus Supplements)., p. 2182

    Side effects of /ranitidine and cimetidine/ that are hard to explain are headache, dizziness, malaise, myalgia, nausea, vomiting, diarrhea, and constipation.

    Haddad, L.M., Clinical Management of Poisoning and Drug Overdose. 2nd ed. Philadelphia, PA: W.B. Saunders Co., 1990., p. 824

    Sexual impotence has occurred in at least one male during ranitidine therapy, but disappeared following discontinuance of the drug; impotence recurred upon rechallenge. Painful gynecomastia also has occurred during oral admin of ranitidine, but disappeared gradually following discontinuance of the drug; gynecomastia reappeared upon rechallenge.

    McEvoy G.K. (ed.). American Hospital Formulary Service-Drug Information 96. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 1996 (Plus Supplements)., p. 2182

    For more Drug Warnings (Complete) data for RANITIDINE (19 total), please visit the HSDB record page.

    5 Pharmacology and Biochemistry
    5.1 MeSH Pharmacological Classification

    Anti-Ulcer Agents

    Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. (See all compounds classified as Anti-Ulcer Agents.)

    Histamine H2 Antagonists

    Drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood. (See all compounds classified as Histamine H2 Antagonists.)

    5.2 FDA Pharmacological Classification
    5.2.1 Pharmacological Classes
    Histamine-2 Receptor Antagonist [EPC]; Histamine H2 Receptor Antagonists [MoA]
    5.3 ATC Code

    A02BA02

    S66 | EAWAGTPS | Parent-Transformation Product Pairs from Eawag | DOI:10.5281/zenodo.3754448

    A02BA02

    S66 | EAWAGTPS | Parent-Transformation Product Pairs from Eawag | DOI:10.5281/zenodo.3754448

    A02BA02

    S66 | EAWAGTPS | Parent-Transformation Product Pairs from Eawag | DOI:10.5281/zenodo.3754448

    A02BA02

    S66 | EAWAGTPS | Parent-Transformation Product Pairs from Eawag | DOI:10.5281/zenodo.3754448

    A - Alimentary tract and metabolism

    A02 - Drugs for acid related disorders

    A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord)

    A02BA - H2-receptor antagonists

    A02BA02 - Ranitidine

    5.4 Absorption, Distribution and Excretion

    Twelve normal male subjects received 20, 40, or 80 mg of ranitidine orally 90 min before starting a 3-hr continuous infusion of pentagastrin, 2 ug/kg/hr. Ranitidine reduced hydrogen ion output by 29%, 50% and 70% & secretion volume by 21%, 37%, and 47%. Pepsin activity was reduced by 8%, 50% & 49% by the same doses. Peak serum concn was correlated positively with percent reduction in hydrogen ion output (r= 0.81, P= less than 0.001) & volume (r= 0.71, P less than 0.01) over a 2-hr period. A 50% inhibition of hydrogen ion output was associated with a peak ranitidine serum concn of 165 ug/l and subjects reached peak serum concn 60 to 120 min after oral dosing.

    PMID:6269788 Lebert PA et al; Clin Pharmacol Ther 30 (4): 539-44 (1981)

    Ranitidine is rapidly absorbed from the GI tract following oral admin and from parenteral sites following IM injection; however, following oral admin, the drug undergoes extensive first-pass metabolism. ... The absolute bioavailability of orally admin ranitidine has been reported to be about 50%; similar oral bioavailability of the drug has been reported in children 3.5-16 yr of age. Following oral admin, area under the plasma conc-time curve may be substantially increased in geriatric individuals compared with younger adults. Following IM admin, the absolute bioavailability of ranitidine is 90-100%.

    McEvoy G.K. (ed.). American Hospital Formulary Service-Drug Information 96. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 1996 (Plus Supplements)., p. 2180

    Following oral admin of 150 mg doses, mean peak serum ranitidine conc of 372-545 ng/ml occur within 2-3 hr and may be positively correlated with age in adults. Following oral admin of single doses of the drug in one study, peak serum conc were biphasic in some individuals with an initial peak occurring @ 0.5-1.5 hr after admin and a second peak occurring about 3 hr after admin. Following IM admin of a single 50-mg dose of the drug, mean peak serum ranitidine conc of 576 ng/ml occur within 15 min.

    McEvoy G.K. (ed.). American Hospital Formulary Service-Drug Information 96. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 1996 (Plus Supplements)., p. 2180

    Ranitidine is widely distributed throughout the body and is 10-19% protein bound. The apparent volume of distribution of ranitidine is reported to be 1.2-1.9 l/kg. The apparent volume of distribution in children 3.5-16 yr of age is reported to be 2.3-2.5 l/kg (range: 1.1-3.7 l/kg).

    McEvoy G.K. (ed.). American Hospital Formulary Service-Drug Information 96. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 1996 (Plus Supplements)., p. 2180

    For more Absorption, Distribution and Excretion (Complete) data for RANITIDINE (32 total), please visit the HSDB record page.

    5.5 Metabolism/Metabolites

    Ranitidine undergoes significant first-pass metabolism after oral admin. It is metabolized in the liver to the pharmacologically inactive desmethylranitidine, ranitidine-N-oxide, and ranitidine-S-oxide.

    American Medical Association, Council on Drugs. AMA Drug Evaluations Annual 1994. Chicago, IL: American Medical Association, 1994., p. 902

    Less than 10% of an iv or oral dose is excreted as metabolites; 68% to 79% of an iv dose and 30% of an oral dose appear in the urine as unchanged drug.

    American Medical Association, Council on Drugs. AMA Drug Evaluations Annual 1994. Chicago, IL: American Medical Association, 1994., p. 902

    The chromatographic behavior of putative N-oxide metabolites relative to the parent amino compounds with the aim of predicting retention data for N-oxides is described. Model compounds were evaluated by reversed phase HPLC and standard TLC systems and the data generated to predict retention values for ranitidine N-oxide and tamoxifen N-oxide based upon those of the parent compounds. The deviation between actual and predicted values was larger than expected.

    PMID:2100636 Ballard P, Law B; J Pharm Biomed Anal 8 (8-12): 877-80 (1990)

    Ranitidine has known human metabolites that include Desmethylranitidine.

    S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560

    5.6 Biological Half-Life

    The elimination half-life of ranitidine in adults averages 1.7-3.2 hr and may be positively correlated with age in adults. The elimination half-life is prolonged in patients with renal impairment. In children 3.5-16 yr of age, the elimination half-life averages 1.8-2 hr (range: 1.4-2.9 hr).

    McEvoy G.K. (ed.). American Hospital Formulary Service-Drug Information 96. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 1996 (Plus Supplements)., p. 2180

    In one study following oral admin of a single 150-mg dose of ranitidine in patients with creatinine clearances averaging 27.2 ml/min, the terminal elimination half-life of ranitidine was 8.7 hr; a correlation between the degree of impairment and the elimination half-life of the drug was not apparent. However, in another study in patients with GFRs ... ranging from 3-69 ml/min per 1.73 sq m, ranitidine clearance was shown to correlate with GFR and elimination half-life of ranitidine was correlated with degree of renal impairment. In a study in patients with creatinine clearances of 0.5-34 ml/min, the elimination half-life ranged from 3-10 hr following IV admin of a single 50-mg dose.

    McEvoy G.K. (ed.). American Hospital Formulary Service-Drug Information 96. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 1996 (Plus Supplements)., p. 2180

    The half-life of ranitidine reportedly is prolonged to about 6 hr in geriatric individuals following oral admin of a 100 mg dose of the drug.

    McEvoy G.K. (ed.). American Hospital Formulary Service-Drug Information 96. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 1996 (Plus Supplements)., p. 2180

    5.7 Mechanism of Action

    H2 antagonists inhibit gastric acid secretion elicited by histamine and other H2 agonists in a dose dependent, competitive manner; the degree of inhibition parallels the concentration of the drug in plasma over a wide range. The H2 antagonists also inhibit acid secretion elicited by gastrin and, to a lesser extent, by muscarinic agonists. Importantly, these drugs inhibit basal (fasting) and nocturnal acid secretion and that stimulated by food, sham feeding, fundic distention, and various pharmacological agents; this property reflects the vital role of histamine in mediating the effects of diverse stimuli. /H2 Receptor Antagonists/

    Gilman, A.G., T.W. Rall, A.S. Nies and P. Taylor (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th ed. New York, NY. Pergamon Press, 1990., p. 899

    ... /H2 Antagonists/ measurably inhibit effects on the cardiovascular and other systems that are elicited through H2 receptors by exogenous or endogenous histamine. /H2 Receptor Antagonists/

    Gilman, A.G., T.W. Rall, A.S. Nies and P. Taylor (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th ed. New York, NY. Pergamon Press, 1990., p. 899

    ...IS A COMPETITIVE ANTAGONIST OF HISTAMINE-INDUCED GASTRIC ACID SECRETION... INHIBITS BOTH THE VOLUME AND CONCENTRATION OF GASTRIC ACID INDUCED NOCTURNALLY AND BY FOOD BUT DOES NOT AFFECT GASTRIC MUCUS OR ITS PRODUCTION. ...DOES NOT AFFECT LOWER ESOPHAGEAL SPHINCTER PRESSURE...

    American Medical Association, Council on Drugs. AMA Drug Evaluations Annual 1994. Chicago, IL: American Medical Association, 1994., p. 901

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Fillers, Diluents & Binders

    read-more
    read-more

    Coating Systems & Additives

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Controlled & Modified Release

    read-more
    read-more

    Film Formers & Plasticizers

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Granulation

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Lubricants & Glidants

    read-more
    read-more

    Parenteral

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Empty Capsules

    read-more
    read-more

    Vegetarian Capsules

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    Coloring Agents

    read-more
    read-more

    Rheology Modifiers

    read-more
    read-more

    Solubilizers

    read-more
    read-more

    Topical

    read-more
    read-more

    Soft Gelatin

    read-more
    read-more

    Surfactant & Foaming Agents

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ANALYTICAL

    Upload your methods for free, ask us

    ABOUT THIS PAGE

    Looking for 82530-72-1 / Ranitidine API manufacturers, exporters & distributors?

    Ranitidine manufacturers, exporters & distributors 1

    34

    PharmaCompass offers a list of Ranitidine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Ranitidine manufacturer or Ranitidine supplier for your needs.

    Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ranitidine manufacturer or Ranitidine supplier.

    PharmaCompass also assists you with knowing the Ranitidine API Price utilized in the formulation of products. Ranitidine API Price is not always fixed or binding as the Ranitidine Price is obtained through a variety of data sources. The Ranitidine Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

    API | Excipient name

    Ranitidine

    Synonyms

    66357-35-5, Ranitidine base, Raticina, Ratic, Ranitidina, Ranitidinum

    Cas Number

    82530-72-1

    About Ranitidine

    A non-imidazole blocker of those histamine receptors that mediate gastric secretion (H2 receptors). It is used to treat gastrointestinal ulcers.

    Vizerul Manufacturers

    A Vizerul manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Vizerul, including repackagers and relabelers. The FDA regulates Vizerul manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Vizerul API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

    click here to find a list of Vizerul manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

    Vizerul Suppliers

    A Vizerul supplier is an individual or a company that provides Vizerul active pharmaceutical ingredient (API) or Vizerul finished formulations upon request. The Vizerul suppliers may include Vizerul API manufacturers, exporters, distributors and traders.

    click here to find a list of Vizerul suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

    Vizerul USDMF

    A Vizerul DMF (Drug Master File) is a document detailing the whole manufacturing process of Vizerul active pharmaceutical ingredient (API) in detail. Different forms of Vizerul DMFs exist exist since differing nations have different regulations, such as Vizerul USDMF, ASMF (EDMF), JDMF, CDMF, etc.

    A Vizerul DMF submitted to regulatory agencies in the US is known as a USDMF. Vizerul USDMF includes data on Vizerul's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Vizerul USDMF is kept confidential to protect the manufacturer’s intellectual property.

    click here to find a list of Vizerul suppliers with USDMF on PharmaCompass.

    Vizerul WC

    A Vizerul written confirmation (Vizerul WC) is an official document issued by a regulatory agency to a Vizerul manufacturer, verifying that the manufacturing facility of a Vizerul active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Vizerul APIs or Vizerul finished pharmaceutical products to another nation, regulatory agencies frequently require a Vizerul WC (written confirmation) as part of the regulatory process.

    click here to find a list of Vizerul suppliers with Written Confirmation (WC) on PharmaCompass.

    Vizerul GMP

    Vizerul Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

    GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

    PharmaCompass offers a list of Vizerul GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Vizerul GMP manufacturer or Vizerul GMP API supplier for your needs.

    Vizerul CoA

    A Vizerul CoA (Certificate of Analysis) is a formal document that attests to Vizerul's compliance with Vizerul specifications and serves as a tool for batch-level quality control.

    Vizerul CoA mostly includes findings from lab analyses of a specific batch. For each Vizerul CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

    Vizerul may be tested according to a variety of international standards, such as European Pharmacopoeia (Vizerul EP), Vizerul JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Vizerul USP).

    Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
    For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search